FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like AbbVie Reports Full-Year and Fourth-Quarter 2016 Financial Results January 26, 2017 MorphoSys AG To Present At Upcoming Investor Conferences August 9, 2017 The Elephant in the Room—Investors Pushing for Lower Pay for 1st Female GlaxoSmithKline CEO March 5, 2017
The Elephant in the Room—Investors Pushing for Lower Pay for 1st Female GlaxoSmithKline CEO March 5, 2017
